– Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Admin

– Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Admin

NEW YORK and NEW ORLEANS, Aug. 21, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charle

– Phase 3 results highlight benefits of ATEV for patients at higher risk of fistula failure, includi

Denali Therapeutics (NASDAQ: DNLI - Get Free Report) and Humacyte (NASDAQ: HUMA - Get Free Report) a

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology company that develops bioengineered

– Jeromy Brink, MD, Mayo Clinic–trained vascular surgeon in Phoenix, is the first surgeon in Arizona

Benchmark analyst Bruce D. Jackson maintains Humacyte (NASDAQ:HUMA) with a Speculative Buy and lo

Humacyte, Inc. (HUMA) Q2 2026 Earnings Call Transcript

Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus E

Humacyte NASDAQ: HUMA reported second-quarter commercial sales growth while outlining plans to expan

Humacyte (NASDAQ:HUMA) reported quarterly losses of $(0.16) per share which missed the analyst conse

– Breakthrough results from V012 dialysis access Phase 3 study, where ATEV was observed to outperfor

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr.,

DURHAM, N.C., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage bi

Humacyte, Inc. (HUMA) concluded the recent trading session at $0.73, signifying a +2.33% move from i

Humacyte, Inc. (HUMA) concluded the recent trading session at $0.63, signifying a -6.44% move from i

– Phase 2a study of CTEV in coronary artery bypass grafting (CABG) is expected to start this quarter

In the latest trading session, Humacyte, Inc. (HUMA) closed at $0.67, marking a +2.22% move from the

Humacyte, Inc. (HUMA) closed at $0.66 in the latest trading session, marking a -1.28% move from the

Humacyte, Inc. (HUMA) closed the most recent trading day at $0.71, moving +2.31% from the previous t

- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple

Gainers Curis (NASDAQ:CRIS) stock rose 9.0% to $0.46 during Wednesday's after-market session. T

The latest trading day saw Humacyte, Inc. (HUMA) settling at $0.78, representing a -2.32% change fro

Humacyte, Inc. (HUMA) concluded the recent trading session at $0.62, signifying a -11.14% move from

TD Cowen analyst Joshua Jennings maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology company that develops bioengineered

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Humacyte (NASDAQ:HUMA) with a Bu

Humacyte (HUMA) stock plummets 22% despite positive Phase 3 ATEV trial data as investors react to a

Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universal

The V012 clinical study is designed to demonstrate the efficacy and safety of the ATEV as a dialysis

Benchmark analyst Bruce D. Jackson maintains Humacyte (NASDAQ:HUMA) with a Speculative Buy and ra

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Humacyte (NASDAQ:HUMA) with a B

- Surgical Implant – Next Generation contract makes Symvess more easily accessible to 170 VA hospita

TD Cowen analyst Joshua Jennings maintains Humacyte (NASDAQ:HUMA) with a Buy and raises the price

BTIG analyst Ryan Zimmerman maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price targ

Top Wall Street analysts changed outlook on top names. Needham downgrades CNTA, Baird downgrades PHR

Small-cap benchmark Russell 2000 ETF hits record high after Fed cuts rates, hinting at more cuts. Sm